文献速递慢阻肺

拓宽肺减容手术的选择标准

Widening the selection criteria for lung volume reduction surgery.
PubMed 文献 · Eur Respir J · 2025-01-16

本文为Eur Respir J一篇评论,指出严重过度充气且异质性形态的患者在超过FEV1和6MWD上限标准时也可考虑肺减容手术,可能获得显著临床获益且术后风险低。文章回顾LVRS通用选择标准,并指出既往专家中心已挑战下限标准,但超过上限标准的数据尚未发表。

要点

  • 严重过度充气且异质性形态患者超过FEV1和6MWD上限标准时也可考虑LVRS。
  • 此类患者可能获得显著临床获益且术后风险低。
  • LVRS通用选择标准源自NETT试验专家建议,含FEV1、TLC、RV、DLCO、6MWD等指标。

核心结论

  • 严重过度充气且异质性形态的患者超过FEV1和6MWD上限标准时也可考虑LVRS,可能获得显著临床获益且术后风险低。

研究设计与样本

  • 本文为Eur Respir J评论文章,基于文献回顾与专家观点,未报告原始研究样本。

主要发现

  • 既往专家中心已报告FEV1<20%预计值和DLCO<20%预计值且形态欠佳但显著过度充气的严重患者可成功接受LVRS。
  • 据作者所知,尚无发表数据探讨超过LVRS上限标准的有症状患者接受LVRS的情况。

关键数值与推荐

  • LVRS通用选择标准源自NETT试验专家建议:FEV1 20–45%预计值。
  • TLC>100%预计值,RV>150%预计值,DLCO≥20%预计值。
  • 6MWD 140–450 m。
  • 无冠心病或中重度肺动脉高压(平均肺动脉压<35 mmHg)。

临床怎么用

  • LVRS患者应由专业多学科团队经全面功能与形态评估后选择。
  • 对严重过度充气且异质性形态但超过FEV1和6MWD上限标准的有症状患者,可考虑LVRS评估。

局限性

  • 本文为评论文章,未提供原始研究数据。
  • 超过LVRS上限标准患者的数据尚未发表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severely hyperinflated patients with a heterogeneous morphology could be considered for lung volume reduction surgery when surpassing the upper limit criteria for FEV1 and 6MWD, resulting in significant clinical benefits with minimal postoperative risks https://bit.ly/4eWTNy8 Lung emphysema is a chronic disease that strongly impairs the patient's quality of life and survival. In well-selected patients with severe emphysema, who are breathless despite maximal medical care, lung volume reduction (LVR) can improve lung function and exercise capacity to alleviate symptoms and potentially delay or prevent lung transplantation [1, 2]. The main goal of LVR is to reduce hyperinflation by targeting the excess residual volume (RV), increasing dynamic lung volumes and breathing reserve capacity [2]. Patients should be selected by a specialised multidisciplinary team following thorough functional and morphological assessment [3]. The general accepted selection criteria for lung volume reduction surgery (LVRS) originate from expert recommendations in the NETT trial and include forced expiratory volume in 1 s (FEV1) 20–45% of predicted, total lung capacity >100% pred, RV >150% pred, diffusing capacity for carbon monoxide (DLCO) ≥20% pred, 6-min walking distance (6MWD) 140–450 m, and absence of coronary artery disease or moderate to severe pulmonary hypertension (mean pulmonary arterial pressure <35 mmHg) [4]. Over the past years, expert centres have challenged the lower inclusion limits by reporting successful outcomes in patients with more severe disease (FEV1 <20% pred and DLCO <20% pred) and less favourable morphology in the presence of significant hyperinflation [5–7]. In contrast to these often-challenging cases, to our knowledge, no data is published on LVRS in symptomatic patients exceeding the upper-limit criteria, once deemed “too good” for LVRS. We hypothesise that these patients with a major impact on functional capacity and quality of life due to hyperinflation could benefit from LVRS.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Vandervelde CM, Everaerts S, Weder W, et al. Widening the selection criteria for lung volume reduction surgery. Eur Respir J. 2025. PMID: 39715645. doi:10.1183/13993003.00829-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。